The Problem

Unlike other companies that are developing technologies to produce Mo-99, Coquí Pharma’s technology is the only proven, demonstrated, safe, and reliable method for commercially scalable Mo-99 production.

Although the U.S. is the world’s largest consumer of medical radioisotopes, it doesn’t have a domestic supply and must rely on imports from Europe and other countries to meet demand. As nuclear reactors around the world continue to age and shut down, securing a reliable commercial source for medical radioisotopes is more important than ever to ensure patients have access to lifesaving diagnostics and treatment.

The Coquí Solution

Coquí Pharma is poised to be the U.S. leader in domestic medical radioisotope production. Coquí Pharma is in the process of licensing and building a dedicated Medical Isotope Production Facility (MIPF) in Oak Ridge, Tennessee. The first of its kind in the U.S., this facility will produce a commercially scalable and reliable source of medical diagnostic and therapeutic radioisotopes, specifically Molybdenum-99 (Mo-99). The facility is expected to be fully operational in 2026.

Unlike other companies that are developing technologies to produce Mo-99, Coquí Pharma’s technology is the only proven, demonstrated, safe, and reliable method for commercially scalable Mo-99 production.